Drugs / TransCon TLR7/8 Agonist
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05980598 | Sep 2023 → Mar 2025 | head and neck squamous cell carcinoma | Ascendis Pharma A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon TLR7/8 Agonist | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05980598 ↗ |
| Known as | TC TLR7/8 | “TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma” NCT05980598 ↗ |
| Action | Activate | “TLR7/8 agonist prodrug” NCT05980598 ↗ |
| Route | Other | “TransCon TLR7/8 Agonist intratumoral (IT) injection” NCT05980598 ↗ |
| Target | TLR7 | “TLR7/8 agonist prodrug” NCT05980598 ↗ |